SCHEMBL3010835

SCHEMBL3010835

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 3/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
MAPK1 P28482 2/20 0.50
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GBA1 P04062 1/20 0.48
RAB9A P51151 2/20 0.46
AR P10275 4/20 0.46
FAAH O00519 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
FABP1 P07148 1/20 0.43
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019779 0.92 MAPT (0.53) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3010509 0.91 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3002461 0.91 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3010640 0.89 AR (0.56) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3017698 0.89 LMNA (0.56) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3018320 0.89 AR (0.55) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3006385 0.86 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3010028 0.86 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3019761 0.85 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL3010515 0.85 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.